China Accepts Sac TMT Lung Cancer Filing

Company Kelun-Biotech Event Type Regulatory filing acceptance (China-source update) Modality TROP2-directed antibody-drug conjugate plus anti-PD-1 Asset Sacituzumab tirumotecan (SKB264/MK-2870) plus pembrolizumab Target TROP2; PD-1 Disease Area First-line PD-L1-negative, EGFR/ALK-negative nonsquamous NSCLC Summary China-source update: Kelun-Biotech’s Chinese-language newsroom listed on 28 October that CDE accepted a…